Krebs Biochemicals revenue halved as Vizag plant stays shut
FY26 revenue fell to ₹2,373.16 lacs from ₹4,331.19 lacs; net loss narrowed to ₹1,693.31 lacs but net worth deepened to negative ₹16,275.47 lacs. Plant remains closed since Feb 2025.
What's new
- FY26 revenue dropped to ₹2,373.16 lacs from ₹4,331.19 lacs a year ago.
- Net loss improved to ₹1,693.31 lacs from ₹2,692.40 lacs.
- Vizag plant remains shut since Feb 2025 pollution board order.
Why this matters
Krebs' only manufacturing plant has been shut for over a year, halving revenue. The marginal loss reduction is insufficient to offset the cash burn. With net worth at negative ₹16,275.47 lacs, the company's viability hinges on restarting the Vizag unit—a scenario with no public timeline.
What we're watching
- Any update on Vizag plant compliance or restart.
- Debt restructuring or equity infusion plans.
- Q1 FY27 performance—whether losses continue to narrow.
The full read
Krebs Biochemicals' FY26 results confirm a company in operational distress. Revenue fell to ₹2,373.16 lacs from ₹4,331.19 lacs as its Vizag plant remained closed since February 2025 following a pollution board order. Net loss narrowed to ₹1,693.31 lacs from ₹2,692.40 lacs, but the improvement is marginal when set against the revenue collapse and net worth that deepened to negative ₹16,275.47 lacs. This is a routine filing with no surprises—the market had already priced in the plant closure. The open question is whether the company can ever restart operations or if this marks a slow unwinding.